Back to Journals » OncoTargets and Therapy » Volume 15

IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction]

Authors Li Y, Chen G, Han Z, Cheng H, Qiao L , Li Y 

Received 16 August 2022

Accepted for publication 16 August 2022

Published 22 August 2022 Volume 2022:15 Pages 871—872

DOI https://doi.org/10.2147/OTT.S386447



Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y. Onco Targets Ther. 2020;13:9721-9730.

The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised regarding the alleged duplication of western blot images in Figure 4. Specifically,

  • Western blot band Figure 4C, IL-6R, Ctrl appears to have been duplicated with western blot band Figure 4E, VEGF, PBS, which has been flipped.

The authors responded to our queries and provided several files. However, the authors were unable to provide a satisfactory explanation for the alleged duplication, nor could they provide satisfactory original western blot data that would support the integrity of their research. The decision was made to retract the article and the authors were notified of this.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.